Shanghai Auzone Biological Technology Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 11, 2027The maintenance fee for Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor (US 10,556,947) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 13 US 12,758,529 Use of Edaravone in Treatment of Autism Spectrum Disorder
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,969,799 | Anti-Human Probdnf Monoclonal Antibody, and Uses Thereof in Pains In force · High confidence | In force | High confidence | |
| US 10,556,947 | Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor In force · USPTO record | In force | USPTO record | |
| US 11,046,746 | Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein In force · USPTO record | In force | USPTO record | |
| US 11,020,375 | Edaravone dosage form In force · USPTO record | In force | USPTO record | |
| US 11,479,603 | Polypeptide and antibody bound to polypeptide In force · USPTO record | In force | USPTO record | |
| US 12,758,529 | Use of Edaravone in Treatment of Autism Spectrum Disorder In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.